D&E Biopharmaceuticals

D&E Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative biologics for oncology and autoimmune diseases. Headquartered in Suzhou, China, with additional research operations in the United States, the company leverages a proprietary antibody engineering platform to develop high-quality therapeutic candidates. Its pipeline includes a mix of bio-better monoclonal antibodies and novel multi-functional fusion proteins designed to improve upon existing standards of care. The lead program, DE001, is an anti-CD20 antibody currently in late-stage clinical development for B-cell malignancies. Other notable assets include a bifunctional PD-L1/TGF-beta trap and a monoclonal antibody targeting Claudin 18.2. D&E Biopharmaceuticals aims to provide globally competitive biopharmaceutical products through efficient R&D and integrated manufacturing capabilities.